Company Filing History:
Years Active: 2025
Title: Innovations of Hyun Cheol Jung in Therapeutics
Introduction
Hyun Cheol Jung is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of therapeutics, particularly in the development of fusion molecules that target disease-related proteins. His innovative work aims to address critical health issues associated with abnormal protein accumulation.
Latest Patents
Hyun Cheol Jung holds a patent for a TAM receptor-binding fusion molecule that exhibits non-inflammatory phagocytosis-inducing activity. This fusion molecule is designed to bind to TAM receptors and target substances whose aberrant accumulation is linked to various diseases. The invention effectively clears and reduces abnormal proteins, such as beta-amyloid, tau, alpha-synuclein, huntingtin, and prion proteins. The fusion molecule has potential applications in the prevention and treatment of proteinosis caused by the abnormal accumulation of these substances. He has 1 patent to his name.
Career Highlights
Hyun Cheol Jung is currently associated with Illimis Therapeutics, Inc., where he continues to advance his research and development efforts. His work is pivotal in creating therapeutic solutions that can significantly improve patient outcomes.
Collaborations
He collaborates with notable colleagues, including Chan Hyuk Kim and Won Suk Chung, who contribute to the innovative projects at Illimis Therapeutics, Inc.
Conclusion
Hyun Cheol Jung's contributions to the field of therapeutics through his innovative fusion molecule represent a significant advancement in addressing diseases related to protein accumulation. His work continues to inspire future research and development in this critical area of health.